bioAffinity Technologies Q2 revenue rises on CyPath Lung demand - BIAF News | RalliesbioAffinity Technologies Q2 revenue rises on CyPath Lung demand
B
BIAF• Outlook
- Company prioritizes expanding physician adoption and utilization in second half of 2026
- bioAffinity plans to advance pipeline for asthma, COPD diagnostics and skin cancer therapeutics
Overview
- US biotechnology firm's Q2 revenue rose 19% yr/yr, driven by CyPath Lung test sales
- CyPath Lung test volume surged 216% yr/yr, reflecting increased physician adoption
- Company completed $3.2 mln public offering to fund commercialization and clinical development
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Revenue | | $1.5 mln | |
| Q2 Net Loss | | $3.4 mln | |
Result drivers
- PHYSICIAN ADOPTION - Co said accelerating physician adoption and integration of CyPath Lung into clinical workflows drove test volume growth
- EXISTING CLIENTS - Existing clients increased CyPath Lung orders by 71% yr/yr during the first six months of 2026
- EDUCATION INITIATIVES - Co expanded physician education efforts, including scientific presentations and webinars, to support adoption
•
